Background:Cancerous cells usually exhibit increased aerobic glycolysis, compared with normal tissue (the Warburg effect), making this pathway an attractive therapeutic target.Methods:Cell viability, cell number, clonogenic assay, reactive oxygen (ROS), ATP, and apoptosis were assayed in MCF-7 tumour cells and corresponding primary human mammary epithelial cells (HMEC).Results:Combining the glycolysis inhibitors 2-deoxyglucose (2DG; 180 mM) or lonidamine (300 μM) with 10 J cm−2 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) increases MCF-7 cytotoxicity (by 3.5-fold to 70% death after 24 h, and by 10-fold in 9-day clonogenic assays). However, glycolysis inhibition only slightly increases HMEC PDT cytotoxicity (between two-fold and three-fold to a maximum of 9% death after 24 h). The potentiation of PDT cytotoxicity only occurred if the glycolysis inhibitors were added after ALA incubation, as they inhibited intracellular accumulation of photosensitiser if coincubated with ALA.Conclusion:As 2DG and lonidamine are already used as cancer chemotherapeutic agents, our results are directly translatable to combination therapies with existing topical PDT.
Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy
J. Golding,T. Wardhaugh,L. Patrick,M. Turner,J. Phillips,J. I. Bruce,S. Kimani
Published 2013 in British Journal of Cancer
ABSTRACT
PUBLICATION RECORD
- Publication year
2013
- Venue
British Journal of Cancer
- Publication date
2013-07-16
- Fields of study
Biology, Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
CONCEPTS
- 2-deoxyglucose
A glucose analogue used here as a glycolysis inhibitor in combination experiments.
Aliases: 2DG
- 5-aminolevulinic acid photodynamic therapy
A photodynamic treatment that uses 5-aminolevulinic acid to generate a photosensitising effect in cells after light exposure.
Aliases: ALA PDT, 5-ALA PDT, ALA photodynamic therapy
- intracellular accumulation of photosensitiser
The amount of photosensitising agent retained inside cells before light activation.
Aliases: photosensitiser accumulation
- lonidamine
A metabolic inhibitor used here to suppress glycolysis in the treatment combinations.
- mcf-7 tumour cells
A human breast cancer cell line used as the tumour-cell model in the experiments.
Aliases: MCF-7 cells
- primary human mammary epithelial cells
Non-transformed human breast epithelial cells used as the normal-cell comparison model in the experiments.
Aliases: HMEC
REFERENCES
Showing 1-43 of 43 references · Page 1 of 1
CITED BY
Showing 1-56 of 56 citing papers · Page 1 of 1